Do analysts prefer BKHA or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, BKHA or TPST?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is BKHA or TPST more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A Tempest Therapeutics N/A -576.56% -134.99%

Does the media prefer BKHA or TPST?

In the previous week, Black Hawk Acquisition had 5 more articles in the media than Tempest Therapeutics. MarketBeat recorded 8 mentions for Black Hawk Acquisition and 3 mentions for Tempest Therapeutics. Black Hawk Acquisition's average media sentiment score of 0.27 beat Tempest Therapeutics' score of 0.26 indicating that Black Hawk Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TPST or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is TPST or EXOZ more profitable?

eXoZymes' return on equity of -292.15% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% eXoZymes N/A -292.15% -158.66%

Does the media favor TPST or EXOZ?

In the previous week, Tempest Therapeutics had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.18 beat Tempest Therapeutics' score of 0.26 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TPST or ANVS?

Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 1,037.44%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings & valuation, TPST or ANVS?

Annovis Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is TPST or ANVS more profitable?

Tempest Therapeutics' return on equity of -576.56% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% Annovis Bio N/A -685.98% -258.77%

Do analysts recommend TPST or ELTX?

Elicio Therapeutics has a consensus price target of $15.00, indicating a potential upside of 747.46%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, TPST or ELTX?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A

Is TPST or ELTX more profitable?

Tempest Therapeutics' return on equity of -576.56% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% Elicio Therapeutics N/A -1,266.43% -139.94%

Do analysts recommend TPST or CELU?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Tempest Therapeutics (TPST) Competitors

$0.68 -0.06 (-8.27%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$0.70 +0.01 (+2.01%)

As of 07:52 AM Eastern

Compare

TPST vs. BKHA, EXOZ, ANVS, ELTX, and CELU

Should you buy Tempest Therapeutics stock or one of its competitors? Tempest Therapeutics's main competitors and comparable companies include Black Hawk Acquisition (BKHA), eXoZymes (EXOZ), Annovis Bio (ANVS), Elicio Therapeutics (ELTX), and Celularity (CELU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tempest Therapeutics compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Black Hawk Acquisition's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Tempest Therapeutics	N/A	-576.56%	-134.99%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Black Hawk Acquisition has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, indicating that its stock price is 273% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Black Hawk Acquisition had 5 more articles in the media than Tempest Therapeutics. MarketBeat recorded 8 mentions for Black Hawk Acquisition and 3 mentions for Tempest Therapeutics. Black Hawk Acquisition's average media sentiment score of 0.27 beat Tempest Therapeutics' score of 0.26 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.5% of Tempest Therapeutics shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Black Hawk Acquisition beats Tempest Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Tempest Therapeutics compare to eXoZymes?

Tempest Therapeutics (NASDAQ:TPST) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Tempest Therapeutics had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.18 beat Tempest Therapeutics' score of 0.26 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

eXoZymes' return on equity of -292.15% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
eXoZymes	N/A	-292.15%	-158.66%

Tempest Therapeutics has a beta of -1.73, meaning that its stock price is 273% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.19, meaning that its stock price is 219% more volatile than the broader market.

eXoZymes has higher revenue and earnings than Tempest Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
eXoZymes	$70K	609.81	-$9.16M	-$1.19	N/A

22.5% of Tempest Therapeutics shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by insiders. Comparatively, 58.0% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

eXoZymes beats Tempest Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Tempest Therapeutics compare to Annovis Bio?

Tempest Therapeutics (NASDAQ:TPST) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 1,037.44%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Annovis Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Tempest Therapeutics has a beta of -1.73, meaning that its share price is 273% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Tempest Therapeutics had 3 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for Annovis Bio. Tempest Therapeutics' average media sentiment score of 0.26 beat Annovis Bio's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Annovis Bio	Neutral

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 15.9% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tempest Therapeutics' return on equity of -576.56% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Annovis Bio	N/A	-685.98%	-258.77%

Summary

Tempest Therapeutics beats Annovis Bio on 7 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Elicio Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat Tempest Therapeutics' score of 0.26 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Elicio Therapeutics	Very Positive

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Elicio Therapeutics has a consensus price target of $15.00, indicating a potential upside of 747.46%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Tempest Therapeutics' return on equity of -576.56% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Tempest Therapeutics has a beta of -1.73, meaning that its share price is 273% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Summary

Elicio Therapeutics beats Tempest Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Celularity?

Tempest Therapeutics (NASDAQ:TPST) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Tempest Therapeutics has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Celularity	$26.55M	1.74	-$91.72M	-$2.73	N/A

Tempest Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -374.87%. Celularity's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Celularity	-374.87%	N/A	-64.45%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tempest Therapeutics has a beta of -1.73, suggesting that its share price is 273% less volatile than the broader market. Comparatively, Celularity has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Tempest Therapeutics' score of 0.26 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Celularity	Positive

Summary

Tempest Therapeutics and Celularity tied by winning 6 of the 12 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.54M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.78	202.90	19.69
Price / Sales	N/A	1,146.43	561.48	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.50	16.70	10.61	6.03
Net Income	-$26.26M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-13.91%	-4.43%	-2.89%	-2.34%
1 Month Performance	-13.13%	-12.49%	-7.37%	-5.31%
1 Year Performance	-94.24%	7.63%	3.00%	-2.94%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	0.6899 of 5 stars	$0.68 -8.3%	N/A	-94.1%	$12.54M	N/A	N/A	4	Short Interest Increase
BKHA Black Hawk Acquisition	N/A	$12.47 +1.6%	N/A	+10.4%	$52.94M	N/A	N/A	N/A	News Coverage
EXOZ eXoZymes	2.0409 of 5 stars	$5.68 +2.9%	N/A	-64.7%	$52.85M	N/A	N/A	32	Gap Up
ANVS Annovis Bio	1.7555 of 5 stars	$1.23 +2.1%	$12.00 +879.6%	-35.5%	$52.28M	N/A	N/A	7
ELTX Elicio Therapeutics	3.2492 of 5 stars	$1.91 -0.4%	$15.00 +684.5%	-83.3%	$50.62M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. BKHA, EXOZ, ANVS, ELTX, and CELU

How does Tempest Therapeutics compare to Black Hawk Acquisition?

Summary

How does Tempest Therapeutics compare to eXoZymes?

Summary

How does Tempest Therapeutics compare to Annovis Bio?

Summary

How does Tempest Therapeutics compare to Elicio Therapeutics?

Summary

How does Tempest Therapeutics compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. BKHA, EXOZ, ANVS, ELTX, and CELU

How does Tempest Therapeutics compare to Black Hawk Acquisition?

Is BKHA or TPST more profitable?

Which has preferable valuation and earnings, BKHA or TPST?

Which has more risk & volatility, BKHA or TPST?

Do analysts prefer BKHA or TPST?

Does the media prefer BKHA or TPST?

Do insiders and institutionals believe in BKHA or TPST?

Summary

How does Tempest Therapeutics compare to eXoZymes?

Does the media favor TPST or EXOZ?

Do analysts recommend TPST or EXOZ?

Is TPST or EXOZ more profitable?

Which has more volatility and risk, TPST or EXOZ?

Which has better valuation and earnings, TPST or EXOZ?

Do institutionals & insiders believe in TPST or EXOZ?

Summary

How does Tempest Therapeutics compare to Annovis Bio?

Do analysts recommend TPST or ANVS?

Which has higher earnings & valuation, TPST or ANVS?

Which has more volatility & risk, TPST or ANVS?

Does the media refer more to TPST or ANVS?

Do institutionals and insiders believe in TPST or ANVS?

Is TPST or ANVS more profitable?

Summary

How does Tempest Therapeutics compare to Elicio Therapeutics?

Does the media refer more to TPST or ELTX?

Do insiders and institutionals have more ownership in TPST or ELTX?

Do analysts recommend TPST or ELTX?

Is TPST or ELTX more profitable?

Which has more risk and volatility, TPST or ELTX?

Which has stronger valuation & earnings, TPST or ELTX?

Summary

How does Tempest Therapeutics compare to Celularity?

Which has higher valuation and earnings, TPST or CELU?

Is TPST or CELU more profitable?

Do analysts recommend TPST or CELU?

Do institutionals & insiders have more ownership in TPST or CELU?

Which has more volatility and risk, TPST or CELU?

Does the media favor TPST or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools